4,191 reports of this reaction
3.1% of all EZETIMIBE reports
#3 most reported adverse reaction
MYALGIA is the #3 most commonly reported adverse reaction for EZETIMIBE, manufactured by Organon LLC. There are 4,191 FDA adverse event reports linking EZETIMIBE to MYALGIA. This represents approximately 3.1% of all 133,800 adverse event reports for this drug.
Patients taking EZETIMIBE who experience myalgia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MYALGIA is moderately reported among EZETIMIBE users, representing a notable but not dominant share of adverse events.
In addition to myalgia, the following adverse reactions have been reported for EZETIMIBE:
The following drugs have also been linked to myalgia in FDA adverse event reports:
MYALGIA has been reported as an adverse event in 4,191 FDA reports for EZETIMIBE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MYALGIA accounts for approximately 3.1% of all adverse event reports for EZETIMIBE, making it one of the most commonly reported side effect.
If you experience myalgia while taking EZETIMIBE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.